ArticleInfection and immunity2019
Characterization of the Mode of Action of Aurodox, a Type III Secretion System Inhibitor from Streptomyces goldiniensis.
Article in Infection and immunity, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 30 citations in OpenAlex.
- Mesolens imaging in microbiology.Essays in biochemistry · 2026Review
- A comprehensive review on bacterial endophytic secondary metabolites: a road map from crude extract to lead molecule production.Frontiers in pharmacology · 2026Review
- Evaluating the protective effects of Aurodox in a murine model of Shiga toxin-producing Escherichia coli.npj antimicrobials and resistance · 2025Article
- Aurodox inhibits type III secretion in multiple Gram-negative pathogens.Open biology · 2024Article
- PurA is the main target of aurodox, a type III secretion system inhibitor.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Microbiota of pest insect Nezara viridula mediate detoxification and plant defense repression.The ISME journal · 2024Article
- Bioprospecting of inhibitors of EPEC virulence from metabolites of marine actinobacteria from the Arctic Sea.Frontiers in microbiology · 2024Article
- Research Progress on Small Molecular Inhibitors of the Type 3 Secretion System.Molecules (Basel, Switzerland) · 2022Review
- Biosynthesis of Aurodox, a Type III Secretion System Inhibitor from Streptomyces goldiniensis.Applied and environmental microbiology · 2022Article
- Genome sequence of the aurodox-producing bacteriumAccess microbiology · 2022Article
- Antibiotic Discovery and Resistance: The Chase and the Race.Antibiotics (Basel, Switzerland) · 2022Review
- Targeting bacterial pathogenesis by inhibiting virulence-associated Type III and Type IV secretion systems.Frontiers in cellular and infection microbiology · 2022Review
- Identification of Translocation Inhibitors Targeting the Type III Secretion System of Enteropathogenic Escherichia coli.Antimicrobial agents and chemotherapy · 2021Article
- The Case against Antibiotics and for Anti-Virulence Therapeutics.Microorganisms · 2021Review
- Fluorothiazinon, a small-molecular inhibitor of T3SS, suppresses salmonella oral infection in mice.The Journal of antibiotics · 2021Article
- Molecular Targets and Strategies for Inhibition of the Bacterial Type III Secretion System (T3SS); Inhibitors Directly Binding to T3SS Components.Biomolecules · 2021Review
- Possible drugs for the treatment of bacterial infections in the future: anti-virulence drugs.The Journal of antibiotics · 2021Review
- Fluorescence Detection of Type III Secretion Using a Glu-CyFur Reporter System inMicroorganisms · 2020Article
- Advances in actinomycete research: an ActinoBase review of 2019.Microbiology (Reading, England) · 2020Review
- Natural Product Type III Secretion System Inhibitors.Antibiotics (Basel, Switzerland) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Recent work has demonstrated that the polyketide natural product Aurodox from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.